NASDAQ:ECYT - Endocyte Stock Price, Price Target & More

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

Endocyte, Inc. (NASDAQ:ECYT) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative return on equity of 34.20% and a negative net margin of 70,510.81%. View Endocyte's Earnings History.

4 equities research analysts have issued 1-year price targets for Endocyte's shares. Their predictions range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.

Some companies that are related to Endocyte include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), OPKO Health (OPK), Emergent Biosolutions (EBS), TESARO (TSRO), Clovis Oncology (CLVS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT) and Arena Pharmaceuticals (ARNA).

News stories about ECYT stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Endocyte earned a news impact score of 0.11 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Endocyte's stock is owned by many different of institutional and retail investors. Top institutional investors include venBio Select Advisor LLC (8.19%), VHCP Management II LLC (6.19%), BlackRock Inc. (2.48%), Rock Springs Capital Management LP (0.97%), Eventide Asset Management LLC (0.50%) and Millennium Management LLC (0.27%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.

ECYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.

ECYT stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, VHCP Management II LLC, Rock Springs Capital Management LP, BlackRock Inc., Eventide Asset Management LLC, Tibra Equities Europe Ltd, Baird Financial Group Inc. and Element Capital Management LLC. View Insider Buying and Selling for Endocyte.

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ECYT stock can currently be purchased for approximately $13.79.

Endocyte has a market capitalization of $1.02 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.